AMGN AMGEN Inc.

$AMGN so AMGN was at $447 pre-novartis phase 3 fail; now AMGEN has eliminated a competitor, lowered its risk profile and provided a new catalyst!!! AMGN should be at $500!!

$AMGN Amgen is upgraded to a buy rating, reflecting strengthened fundamentals and a robust long-term growth outlook. Q2 saw a significant growth rebound, with 22 products posting at least double-digit sales growth and key drivers like Tezspire and Repatha accelerating. Profitability remains respectable despite cost of sales pressures; AMGN raised full-year 2026 revenue and EPS guidance, signaling improved confidence. The recent selloff from a competitor's trial setback appears overdone; AMGN's forward P/E discount to the sector presents a compelling valuation opportunity.

$AMGN Just sharing: this is gonna change lives and the entire biopharma industry. Check out ICU. Their new device saves half of the people who would otherwise die from sepsis due to cytokine storm. Billions in TAM, about to roll out not just for kids but soon for adults in 2027 and no one realizes the import. 6 Breakthrough Device Designations ranging from Kidney, to Cardio, to Respiratory, cancer patients, infectious diseases... Unreal we can get in on the ground floor. $BMY $SNY $GSK $BIIB

$AMGN oh sheet! Never denied, always delayed. Another 10%+ 🚀 ripper within just days memorialized into the stocktits records. No longer am i doing what I do for Simons’ successor. I am now doing this for Howard. Call me bro. I can help you. $SPY

$AMGN Folks, this is gonna change lives and the entire biopharma industry. Check out ICU. I can't believe the broader market is sleeping on this. Saves half of the people who would otherwise die from sepsis due to cytokine storm. Billions in TAM, about to roll out not just for kids but soon for adults in 2027 and no one realizes the import. 6 Breakthrough Device Designations ranging from Kidney, to Cardio, to Respiratory. Unreal we can get in on the ground floor. $GILD $VRTX $LLY $AZN

$AMGN My last alert long on AMGN was @ 329$ entry alertback in may with 388$ target 1 and open target 2. Since this time I have added back to my position on last week dip below 388$ on a bullish momentum trigger at 380$ (yellow candle print). If 388$ can hold on daily there is now room for the next leg to 540$.

How much per gallon do retina anti vegfs cost? $AMGN $REGN $BAYRY #Congrats to $OTLK on a wholesale acquisition cost of $485 for #bevacizumab in the #UnitedStates! #affordable #eyecare #healthcare #investing #trending Is FDA approved bevacizumab about 36.7 million per gallon?

$AMGN Amgen stock fell sharply after Novartis' cholesterol drug Pelacarsen failed a Phase 3 trial, despite Amgen not being directly involved. Amgen's own cholesterol candidate, Olpasiran, differs significantly from Pelacarsen in potency and dosing, and its outcomes data is not expected until 2028. Repatha, Amgen's established PCSK9 drug, grew revenue 37% year-over-year last quarter, showing the sell-off was driven by sentiment rather than fundamentals.

$AMGN up 2.5% after a price-target hike to $380 from $362 at Truist. Amgen stock is now 26% higher on the year and boasts a nearly 40% year-over-year gain the 80-day moving average provided a springboard last month

$AMGN breach suit: a class action filed Aug 6 alleges patient health data was stolen from Amgen third-party cloud environments disclosed in a July 31 SEC filing. Early stage, no class certified, nothing to claim. Open Class Actions.

$AMGN this has had the illest cup and handle break out ive seen in a long time Cant believe i missed it. Huge gap, wonder if it will fill back to the top ?

$AMGN has staged quite the bounce off its 80-day Put skew on the 50-day BTO p/c ratio, too

$AMGN Amgen maintains a unique position by leveraging its existing commercial infrastructure from the PCSK9 inhibitor Repatha while simultaneously testing olpasiran. This dual-asset strategy allows the company to potentially capture the market regardless of whether physicians prefer established antibody therapies or the newer, high-potency siRNA approach. Amgen's dual lipid strategy positions olpasiran at the center of a "lipoprotein(a) outcomes race," giving the company a two-modality bench that few competitors can currently match.

$AMGN Amgen recently gained attention following positive Phase 3 clinical data and an FDA label update for IMDELLTRA that reduces initial patient monitoring time from roughly a full day down to 6 to 8 hours.Key Pipeline and Business UpdatesIMDELLTRA Progress: The shortened observation window makes administration much more practical for community oncology clinics, broadening the potential treatment pool for small cell lung cancer.Strong Growth Drivers: Amgen's core product sales and key growth drivers rose 26% year-over-year in recent quarters, pushing total revenue past $10 billion.MariTide Development: The company continues to highlight the advancement of its pipeline candidate MariTide for chronic weight management and related Phase 3 studies

$AMGN came in here at 393 too early...a starter but still hurts...adding a tad higher than 353 area. GLTY.